Tevogen Bio Holdings Inc. (NASDAQ:TVGN) revealed plans to broaden the scope of its TVGN 489 experimental medication to encompass patients 65 years of age and above.
A laboratory technician researching a sample of cells in a biotechnology laboratory.
The action expands upon the company's October 2024 revenue forecast of around $1 billion in sales during the first year, with five-year projections ranging from $18 billion to $22 billion. The expanded market will be reflected in an updated risk-adjusted net present value.
Sadiq Khan, MBA, Chief Commercial Officer, stated that the strategic choice coincides with a spike in instances of the highly contagious COVID variant NB.1.8.1, which was initially identified in China. Tevogen Bio Holdings Inc. (NASDAQ:TVGN) is increasing clinical production to satisfy consumer demand.
TVGN 489 targets SARS-CoV-2 infections in immunocompromised patients, such as those with psoriatic arthritis, rheumatoid arthritis, B-cell tumors, and other malignancies. It was created utilizing Tevogen Bio Holdings Inc. (NASDAQ:TVGN)s ExacTcell platform. It covers Long COVID as well. Since seniors (65 and above) were not taken into consideration in earlier forecasts, their inclusion in the specialty care pipeline significantly boosts commercial potential.
While we acknowledge the potential of TVGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TVGN and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.
